Jacek S. Malyszko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacek S. Malyszko has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Jolanta Malyszko
Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, 02-097 Warsaw, Poland
5 shared publications - Ewa Koc-Zorawska
2nd Department of Nephrology, Hypertension and Internal Medicine with Dialysis Unit, Medical University of Bialystok, 15-089 Bialystok, Poland
2 shared publications - Michal Mysliwiec
State University of Applied Sciences, Łomza, Poland
2 shared publications Adrian Iaina
Head Nephrology, APC Health-Specialists Clinics, Benei Berak, Israel
1 shared publication- Alicja Dębska-Ślizień
Department of Nephrology, Transplantology and Internal Medicine, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland
1 shared publication - Beata Bzoma
Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, Gdańsk, Poland
1 shared publication
Latest Publications
- 2 November 2022
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 26 (11) , 995-1009
Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
Altered lipid distribution and metabolism may lead to the development and/or progression of chronic kidney disease (CKD). Dyslipidemia is a major risk factor for CKD and increases the risk of cardi...
- 2 November 2022
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 26 (11) , 995-1009
Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
Altered lipid distribution and metabolism may lead to the development and/or progression of chronic kidney disease (CKD). Dyslipidemia is a major risk factor for CKD and increases the risk of cardi...
- Open Access
- 23 December 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (51) , e28159
Early outcomes and long-term survival after kidney transplantation in elderly versus younger recipients from the same donor in a matched-pairs analysis
The elderly are the fastest-growing population on waiting lists for kidney transplantation (KTx). Recognized barriers to KTx in the elderly is early post-transplant mortality and morbidity. To analyze the outcomes of KTx in recipients older than 60 years and, simultaneously, in their younger paired recipients, receiving a graft from the same donor. We included 328 kidney transplant recipients in the study. The elderly kidney transplant recipients (EKT) group included 164 patients aged 65 standard deviation (SD4) years. They were paired with younger kidney transplant recipients (YKT) aged 45 (SD12) years. The studied groups (EKT vs YKT) did not differ from the graft function estimated 1 year after the transplantation (50.7 mL/min vs 54.0 mL/min), while the estimated glomerular filtration rate decline was significantly faster in the YKT group. One-year patient survival (93.9% vs 97.0%), 1-year graft survival (90.4% vs 82.3%), and incidences of delayed graft function and acute rejection did not differ between the EKT and YKT groups. Significantly more cardiovascular complications and post-transplant diabetes mellitus were noticed in the EKT group. The long-term patient and graft survivals were poorer in the EKT group versus the YKT group, but death-censored graft survivals were the same. After having excluded donor-derived graft factors, there were no differences in the first-year outcome of KTx between recipients younger and older than 60 years. As life expectancy is lower in the EKT group, the probability of patient and graft survival was also significantly lower in this group. However, death-censored graft survival was not different in the EKT and YKT groups.
- 23 December 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (51) , e28159
Open AccessEarly outcomes and long-term survival after kidney transplantation in elderly versus younger recipients from the same donor in a matched-pairs analysis
The elderly are the fastest-growing population on waiting lists for kidney transplantation (KTx). Recognized barriers to KTx in the elderly is early post-transplant mortality and morbidity. To analyze the outcomes of KTx in recipients older than 60 years and, simultaneously, in their younger paired recipients, receiving a graft from the same donor. We included 328 kidney transplant recipients in the study. The elderly kidney transplant recipients (EKT) group included 164 patients aged 65 standard deviation (SD4) years. They were paired with younger kidney transplant recipients (YKT) aged 45 (SD12) years. The studied groups (EKT vs YKT) did not differ from the graft function estimated 1 year after the transplantation (50.7 mL/min vs 54.0 mL/min), while the estimated glomerular filtration rate decline was significantly faster in the YKT group. One-year patient survival (93.9% vs 97.0%), 1-year graft survival (90.4% vs 82.3%), and incidences of delayed graft function and acute rejection did not differ between the EKT and YKT groups. Significantly more cardiovascular complications and post-transplant diabetes mellitus were noticed in the EKT group. The long-term patient and graft survivals were poorer in the EKT group versus the YKT group, but death-censored graft survivals were the same. After having excluded donor-derived graft factors, there were no differences in the first-year outcome of KTx between recipients younger and older than 60 years. As life expectancy is lower in the EKT group, the probability of patient and graft survival was also significantly lower in this group. However, death-censored graft survival was not different in the EKT and YKT groups.
- 1 July 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (6) , 1790-1793
Underrecognition and Underestimation of Disturbances in Calcium-Phosphate Balance in Kidney Transplant Recipients
- 1 July 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (6) , 1790-1793
Underrecognition and Underestimation of Disturbances in Calcium-Phosphate Balance in Kidney Transplant Recipients
- Open Access
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 941
Hemojuvelin and Iron Metabolism in Kidney and Heart Allograft Recipient
- 27 November 2012
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (10S) , 941
Open AccessHemojuvelin and Iron Metabolism in Kidney and Heart Allograft Recipient
- Open Access
- 1 January 2010
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 5 (5) , 744-747
Serum neutrophil gelatinase-associated lipocalin as a marker of kidney function in pregnancy – useful or doubtful?
Introduction : The aim of the study was to assess whether neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C could reflect kidney function in pregnant healthy women. Material and methods : The studies were performed on 130 healthy pregnant women (n = 63, 3rd trimester; n =...
- 1 January 2010
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 5 (5) , 744-747
Open AccessSerum neutrophil gelatinase-associated lipocalin as a marker of kidney function in pregnancy – useful or doubtful?
Introduction : The aim of the study was to assess whether neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C could reflect kidney function in pregnant healthy women. Material and methods : The studies were performed on 130 healthy pregnant women (n = 63, 3rd trimester; n =...
- 21 August 2009
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 32 (4) , 235-238
Serum Prohepcidin and Hepcidin in Hemodialyzed Patients Undergoing Iron Therapy
Hepcidin is the predominant negative regulator of iron absorption in the small intestine, iron transport across the placenta, and iron release from the macrophages. Iron supplementation is often introduced in dialyzed patients to replete or to maintain iron stores, particularly in patients treated with erythropoietin-stimulating agents. The aim of this study was to assess hepcidin levels in 12 hemodialyzed (HD) patients (6 females, 6 males, mean age 64 years, mean time on HD 36 months) before and after intravenous iron therapy. Prohepcidin and hepcidin were studied using commercially available kits from DRG Instruments GmbH, Marburg, Germany (ELISA method), and Bachem, St. Helens, UK (RIA method). Soluble receptor of transferrin was studied using a kit from R&D, Abington, UK. We found a significant rise in hemoglobin concentration, hematocrit, ferritin, serum iron, transferrin saturation and a fall in soluble receptor of transferrin. Serum hepcidin and prohepcidin as well as urinary prohepcidin increased significantly after the therapy. In conclusion, hepcidin levels are influenced by iron supplementation in HD patients. Further examinations of hepcidin as a marker of iron deficiency using new validated measurement techniques are required. It remains to be seen if assay of hepcidin will be of help in identifying patients unresponsive to oral iron or requiring intravenous iron supplementation.
- 21 August 2009
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 32 (4) , 235-238
Serum Prohepcidin and Hepcidin in Hemodialyzed Patients Undergoing Iron Therapy
Hepcidin is the predominant negative regulator of iron absorption in the small intestine, iron transport across the placenta, and iron release from the macrophages. Iron supplementation is often introduced in dialyzed patients to replete or to maintain iron stores, particularly in patients treated with erythropoietin-stimulating agents. The aim of this study was to assess hepcidin levels in 12 hemodialyzed (HD) patients (6 females, 6 males, mean age 64 years, mean time on HD 36 months) before and after intravenous iron therapy. Prohepcidin and hepcidin were studied using commercially available kits from DRG Instruments GmbH, Marburg, Germany (ELISA method), and Bachem, St. Helens, UK (RIA method). Soluble receptor of transferrin was studied using a kit from R&D, Abington, UK. We found a significant rise in hemoglobin concentration, hematocrit, ferritin, serum iron, transferrin saturation and a fall in soluble receptor of transferrin. Serum hepcidin and prohepcidin as well as urinary prohepcidin increased significantly after the therapy. In conclusion, hepcidin levels are influenced by iron supplementation in HD patients. Further examinations of hepcidin as a marker of iron deficiency using new validated measurement techniques are required. It remains to be seen if assay of hepcidin will be of help in identifying patients unresponsive to oral iron or requiring intravenous iron supplementation.
- Open Access
- 1 April 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 49 (4) , B58
134
- 1 April 2007
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 49 (4) , B58
Open Access134